Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Eisai: Clinical Trials & FDA Approval Profile

Eisai (Tokyo, JP / Nutley, NJ) sponsors 31 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (3 recruiting now), 18 completed protocols, and 15 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.9%
Median Closed Enrollment vs National (145 pts)53 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Eisai
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)31
Active Pipeline (Recruiting Now)9 (3)
Completed vs Stopped Early18 / 4 (12.9%)
Median Closed Actual Enrollment53 participants
Physical Hospital Site Disclosure96.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals15 (3 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Eisai
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA8
Washington University and Siteman Cancer CenterSaint Louis, MO6
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MD6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Eisai
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07515014A Study of E6742 in Participants With Systemic Lupus ErythematosusPhase IIRECRUITING
NCT07493265A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyPhase IIRECRUITING
NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePhase IIIACTIVE NOT RECRUITING
NCT04015141A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsPhase IIACTIVE NOT RECRUITING
NCT04549168A Study of Lemborexant in Chinese Participants With Insomnia DisorderPhase IIICOMPLETED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Eisai Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI